Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient

Ann Oncol. 2017 Sep 1;28(9):2318-2319. doi: 10.1093/annonc/mdx252.

Authors

M Ito¹, S Fujiwara², D Fujimoto¹, R Mori¹, H Yoshimura², A Hata³, N Kohara², K Tomii¹

Affiliations

¹ Departments of Respiratory Medicine.
² Neurology, Kobe City Medical Center General Hospital, Kobe.
³ Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan.

PMID: 28911080
DOI: 10.1093/annonc/mdx252

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Brain Neoplasms / cerebrospinal fluid
Brain Neoplasms / drug therapy
Brain Neoplasms / secondary
Encephalitis / cerebrospinal fluid
Encephalitis / chemically induced
Humans
Ipilimumab / administration & dosage
Ipilimumab / adverse effects
Lung Neoplasms / cerebrospinal fluid
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Nivolumab
Rituximab / therapeutic use*
Small Cell Lung Carcinoma / cerebrospinal fluid
Small Cell Lung Carcinoma / drug therapy*
Small Cell Lung Carcinoma / pathology

Substances

Antibodies, Monoclonal
Ipilimumab
Nivolumab
Rituximab